Andarix Pharmaceuticals CEO to Highlight Advances in Cancer Clinical Trials at Industry Conference

Targeted Peptide Therapy and Pioneering Cancer Clinical Trials Featured at Upcoming Event

Boston, MA, United States, 17th Jul 2025 — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapies for rare cancers, announced today that CEO Chris Adams will deliver a keynote presentation at the Clinical Trials in Oncology Conference, taking place July 8–9, 2025, in Boston, Massachusetts. This pivotal event will focus on accelerating cancer clinical trials and innovative strategies to address unmet needs in cancer research, with special emphasis on rare and difficult-to-treat cancers.

Industry experts, clinical operations professionals, and patient advocacy groups are set to attend, reflecting the conference’s broad relevance to both common and rare cancer trial communities. Mr. Adams will share updates on Andarix Pharmaceuticals’ cancer-focused clinical trial programs, detail the company’s experience designing trials for rare cancer indications, and discuss best practices for enhancing patient recruitment and regulatory engagement.

Key Topics of the Conference

• Innovations in Cancer Clinical Trials:
  Latest methods in trial design, including adaptive protocols and biomarker-driven enrollment for cancer therapies.
• Challenges in Rare Cancer Clinical Research:
  Strategies for overcoming patient recruitment barriers, building robust registries, and engaging with diverse research communities.
• Collaboration with Patient Advocacy Groups:
  Fostering early and continuous involvement of patients to improve trial outcomes and retention.
• Regulatory and Operational Excellence:
  Importance of early regulatory planning and cross-stakeholder communication to efficiently bring novel cancer therapies to market.

 

About Andarix Pharmaceuticals

Andarix Pharmaceuticals is at the forefront of personalized cancer therapies, advancing platforms that combine diagnostic imaging agents for patient selection and targeted peptide therapeutics. The company’s lead programs employ a proprietary somatostatin peptide conjugate, which leverages the overexpression of somatostatin receptors on solid tumors—most notably lung, neuroendocrine, and pancreatic cancers. Andarix’s technology and early-phase clinical development efforts are aimed at meeting the critical needs of patients with limited treatment options, and the results from these cancer clinical trials are informing the next generation of precision therapies.

To learn more about Andarix Pharmaceuticals and its clinical trial programs, please visit www.andarix.com.

 

 

Media Contact

Organization: Andarix Pharmaceuticals

Contact Person: Chris Adams

Website: https://andarix.com

Email: Send Email

Contact Number: +16179579858

Address:1660 Soldiers Field Rd

City: Boston

State: MA

Country:United States

Release id:30903

Disclaimer: The information provided in this release is for general informational purposes only and does not constitute medical advice, an endorsement of any product or therapy, or a recommendation for participation in any clinical trial. All clinical programs and outcomes mentioned are subject to regulatory oversight and may be subject to change. Readers are encouraged to consult qualified professionals for medical or scientific guidance.

The post Andarix Pharmaceuticals CEO to Highlight Advances in Cancer Clinical Trials at Industry Conference appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.